32 completed, 7 unknown, 4 terminated, 2 withdrawn. 16 Phase 4, 11 Phase 2, 10 Phase 3, 5 Not applicable, 2 Phase 1.
Follow Xalatan: new trials by email Literature Review of Xalatan trials Research Report on Xalatan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells Xalatan, Monoprost - Glaucoma, Ocular Hypertension | Phase 4 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 28 | 2021-09-01 | 2023-11-18 |
| Nailfold Capillary Blood Flow With Latanoprost Bunod Latanoprost 0.005%, Latanoprost bunod 0.024%, Normal saline 0.9% - Glaucoma, Open-Angle | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 47 | 2019-08-15 | 2021-09-29 |
| Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients Latanoprost 0.005% Ophthalmic Solution, Travoprost 0.004% ophthalmic solution, Tafluprost Ophthalmic 0.0015% Ophthalmic Solution - Primary Open Angle Glaucoma | Completed | Kasr El Aini Hospital | 60 | 2019-06-01 | 2020-07-08 | |
| Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost Monoprost, Xalatan - Glaucoma, Ocular Hypertension | Phase 4 | Completed | CHA University | 57 | 2019-04-30 | 2021-02-08 |
| Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients. Xalost S, Xalatan, Taflotan-S - Glaucoma | Phase 4 | Unknown | Taejoon Pharmaceutical Co., Ltd. | 144 | 2018-12-19 | 2019-11-15 |
| A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT DE-117, Latanoprost ophthalmic solution - Open Angle Glaucoma or Ocular Hypertension | Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 370 | 2017-01-01 | 2024-03-15 |
| 28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension Latanoprost, SAR366234 - Open Angle Glaucoma -Ocular Hypertension | Phase 1 | Completed | Sanofi | 54 | 2015-09-01 | 2016-04-27 |
| A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Xalatan, Apo-Latanoprost, Co-Latanoprost - POAG, Primary Open Angle Glaucoma | Phase 4 | Unknown | Dr. David Yan | 60 | 2015-09-01 | 2017-07-26 |
| Stop Retinal Ganglion Cell Dysfunction Study Latanoprost, Bimatoprost, Travoprost - Glaucoma | Phase 3 | Terminated | University of Miami | 28 | 2015-09-01 | 2025-08-26 |
| Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension T-2345, Xalatan - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Nephron Pharmaceuticals Corporation | 335 | 2014-01-01 | 2018-08-22 |
| Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension Generic latanoprost, Brand-name latanoprost - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Terminated | CHU de Quebec-Universite Laval | 60 | 2014-01-01 | 2017-07-25 |
| A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Trabodenoson, Latanoprost, Timolol - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 101 | 2013-08-01 | 2017-12-02 |
| Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Aqueous Suppressant Eye Drops - Glaucoma | Phase 4 | Unknown | Credit Valley EyeCare | 150 | 2012-02-01 | 2017-07-21 |
| Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy 0.005% Latanoprost dosed once. - Glaucoma | Phase 2 | Unknown | Nanduri, Padma, M.D., FACS | 22 | 2011-09-01 | 2011-08-31 |
| Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature Brimonidine, Latanoprost, Placebo - Primary Vascular Dysregulation | Not applicable | Completed | University Hospital, Basel, Switzerland | 40 | 2011-06-01 | 2013-12-11 |
| Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma dorzolamide/timolol, latanoprost - Normal Tension Glaucoma | Not applicable | Completed | The Catholic University of Korea | 44 | 2011-03-01 | 2015-01-08 |
| Effects of Anti-Glaucoma Medications on the Ocular Surface Travoprost, Latanoprost - Glaucoma | Phase 4 | Terminated | Massachusetts Eye and Ear Infirmary | 14 | 2011-02-01 | 2017-03-16 |
| Safety Study of Latanoprost Slow Release Insert Latanoprost, Arm 2, Latanoprost SR insert - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 | Terminated | Daniel Moore | 12 | 2011-01-01 | 2014-12-08 |
| Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension BOL-303259-X, Latanoprost - Intraocular Pressure | Phase 2 | Completed | Bausch & Lomb Incorporated | 413 | 2010-12-13 | 2018-07-24 |
| Transconjunctival Needling Revision Versus Medical Treatment Transconjunctival needling revision, Medical treatment - Primary Open Angle Glaucoma | Phase 2 | Completed | University of Sao Paulo General Hospital | 40 | 2010-05-01 | 2013-06-27 |
Showing 20 of 46. Sign in to see all of them.
Ocular Hypertension (26) · Glaucoma (25) · Glaucoma, Open-Angle (23) · Hypertension (4) · Dry Eye Syndromes (2) · Diabetic Retinopathy (1) · Hyperemia (1) · Low Tension Glaucoma (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (7) · Alcon Research (6) · University of Miami (2) · Advanced Glaucoma Specialists (1) · Aristotle University Of Thessaloniki (1) · Bausch & Lomb Incorporated (1) · CHA University (1) · CHU de Quebec-Universite Laval (1) · Centre de recherche du Centre hospitalier universitaire de Sherbrooke (1) · Copenhagen University Hospital, Rigshospitalet (1) · Credit Valley EyeCare (1) · Daniel Moore (1) · Dr. David Yan (1) · Icahn School of Medicine at Mount Sinai (1) · Inotek Pharmaceuticals Corporation (1)
United States (24) · Canada (5) · South Korea (3) · Denmark (2) · Brazil (1) · Egypt (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Japan (1) · Singapore (1) · Switzerland (1)
Amandeep S Rai, MD (1) · Anastasios G Konstas, MD, PhD (1) · Barbara Burger, R.N. (1) · Bruce Shields, MD (1) · Carl B Camras, MD (1) · Chan Kee Park, M.D., PhD. (1) · Daniel B. Moore, M.D. (1) · David B Yan, M.D., F.R.C.S. (C) (1) · David S Greenfield, MD (1) · Devesh K Varma, MD FRCSC (1) · Ike K Ahmed, MD FRCSC (1) · Josef Flammer, MD (1) · Kathrine K Tilma, MD (1)
PMID 20142538, PMID 22332206, PMID 24212847, PMID 25488946, PMID 26756747, PMID 28617732, PMID 9261306
2019 (1), R01EY014957 (1)